IDXG Stock Analysis
ID
Uncovered
Interpace Biosciences Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Interpace Biosciences, Inc. engages in the development and sale of diagnostic clinical and pharma services. The company is headquartered in Parsippany, New Jersey and currently employs 147 full-time employees. The Company, through its Interpace Diagnostics, provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology. The company has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, which is for the diagnosis & prognosis of pancreatic cancer from pancreatic cysts; PanDNA, which is a molecular version of PancraGEN that provides physicians a snapshot of a limited number of factors; ThyGeNEXT, which is for diagnosis of thyroid cancer from thyroid nodules utilizing a sequencing assay; ThyraMIR, which is for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay, and RespriDX, which differentiates lung cancer of primary versus metastatic origin.